John Rigg, Exelead CEO
Manufacturing reorg at Merck KGaA inspires a $500M+ investment in mRNA tech
Just weeks after Merck KGaA reorganized its CDMO and contract testing unit around the $780 million buyout of LNP player Exelead, the pharma player has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.